_edited.png)
Can Weed Feel Like Magic Mushrooms? Johns Hopkins Study
- Bud Lords
- 7 hours ago
- 6 min read
Can a high dose of oral cannabis produce a trip similar to magic mushrooms? A pilot study from researchers at Johns Hopkins University examined whether oral tetrahydrocannabinol (THC) can mirror the subjective effects of psilocybin when administered in a therapeutic research setting. The preliminary findings, originally reported by High Times, show that dose, environment, and mindset play a massive role in shaping the cannabis experience.
While cannabis and psilocybin belong to completely different pharmacological classes, high doses of THC can blur the psychological boundaries between a heavy high and a classic trip. For consumers in Washington DC, Maryland, and Virginia, these scientific insights shed fresh light on edible dosing, set and setting, and emerging plant medicine policy.
Johns Hopkins Pilot Study Compares THC and Psilocybin
Published on August 27, 2026, in the journal Psychopharmacology, the pilot study evaluated four healthy adult participants aged 31 to 47. Across separate double-blind sessions, each volunteer received a placebo, 25 mg of psilocybin, and 25 mg of oral THC. Two of the participants also received a higher 50 mg dose of THC in additional sessions.
The researchers tested two distinct oral THC formats during the trial. Two participants received dronabinol, a synthetic formulation featuring over 99% pure THC. The other two volunteers received a botanical cannabis distillate containing 89.9% THC alongside minor cannabinoids.
Because the trial featured only four participants—all white, non-Hispanic, and three holding postgraduate degrees—the researchers noted that inferential statistical analyses were impossible. The study was designed as a pilot to detect preliminary signals rather than draw sweeping population claims.
Set, Setting, and High-Dose THC Phenomenology
To isolate the psychological impact, Johns Hopkins researchers placed participants in an environment identical to classic psychedelic clinical trials. Volunteers lay on a comfortable couch wearing eye shades while listening to a curated music playlist. Two trained facilitators accompanied each participant, encouraging them to focus their attention inward throughout the session.
Under these specific conditions, 25 mg of oral THC produced altered-state profiles that qualitatively resembled those produced by 25 mg of psilocybin. When evaluated on standardized clinical scales measuring mystical-type experiences and altered states of consciousness, both synthetic dronabinol and botanical distillate scored remarkably close to psilocybin.
Interestingly, participants who received synthetic dronabinol rated their experience as closer to a classic psychedelic or dissociative than to standard cannabis. Those taking the botanical distillate correctly identified it as cannabis, yet reported a stronger overall subjective effect than those given pure synthetic dronabinol.
How THC and Psilocybin Interact with the Brain Differently
Despite overlapping subjective experiences, the study emphasizes that cannabis and psychedelic mushrooms do not work through the same brain mechanisms. Psilocybin is a classic psychedelic that acts primarily on serotonin signaling, binding specifically to 5-HT2A receptors in the brain.
Conversely, THC activates the human endocannabinoid system, targeting CB1 receptors located throughout the central nervous system. The research compares phenomenology rather than direct pharmacology, showing that two separate biological pathways can produce surprisingly similar internal journeys.
Increasing the dose to 50 mg of THC did not simply amplify the psychedelic qualities. Instead, the higher dose shifted the experience toward sedation and dissociation, proving that higher cannabinoid concentrations do not scale linearly into classic psychedelic trips.
A Brief History of Psychedelic Cannabis Science
This pilot study builds upon several prior research papers examining high-potency THC. In 2018, Johns Hopkins researchers published a case report on a 30-year-old male who experienced visual and auditory hallucinations after vaporizing 25 mg of THC during a controlled trial, yielding subjective scores similar to psilocybin.
In 2021, researchers at the University at Albany analyzed retrospective reports of intense THC experiences. They found that between 17% and 19% of participants reached "breakthrough" levels of oceanic boundlessness—a key dimension of mystical experiences—compared to 59% typically reported in psilocybin clinical trials.
A controlled 2022 study evaluated 25 infrequent cannabis users given placebo, 7.5 mg, or 15 mg of oral THC. The researchers recorded dose-dependent increases in insightfulness and language entropy, a structural language phenomenon previously documented in LSD research trials.
THC as an Active Control in Psychedelic Clinical Trials
In a 2023 literature review published online and later featured in the January 2024 issue of Journal of Psychopharmacology, Johns Hopkins researchers suggested high-THC cannabis could address a major flaw in psychedelic clinical trials: functional unblinding. In standard trials, participants and researchers easily guess who received a placebo because classic psychedelic effects are so unmistakable.
By using high-dose THC as an active control comparator, clinical trials could make control conditions harder to identify. Because high doses of oral THC in structured settings trigger intense altered states through a non-serotonergic mechanism, THC could potentially serve as a control benchmark in future psychedelic trials.
The researchers emphasize that far larger, more diverse clinical studies across various dosage ranges are required to validate THC as a clinical trial control. However, these initial findings highlight how significantly set, setting, and dosage influence consumer experiences.
What This Means for Virginia Residents
For consumers navigating Virginia marijuana laws, understanding edible dosing and potency is essential. Under current Virginia cannabis decriminalization and adult-use possession guidelines, adult residents over 21 may legally possess up to one ounce of cannabis in public, though commercial adult-use retail and delivery frameworks remain subject to evolving state legislation.
As DMV consumers explore medical dispensaries, legal adult-use options, or regional delivery services, dosage control remains critical. High-potency edibles containing 25 mg of THC or more can trigger intense, unexpected psychological experiences, especially for infrequent consumers or those in reflective settings.
Virginia residents interested in high-potency cannabinoid products should pay close attention to lab-tested milligram content, starting with low doses like 2.5 mg to 5 mg. Recognizing that set and setting alter the intensity of oral THC helps consumers safely navigate both therapeutic and adult use.
How This Compares to Other States
Across the country, state regulators treat high-potency edibles with varying degrees of oversight. In states like Washington and California, single-serving adult-use recreational edibles are strictly capped at 10 mg of THC per unit, with total package limits generally capped at 100 mg.
In contrast, medical markets in Maryland and specific legal jurisdictions allow higher single-dose caps for qualifying patients. Meanwhile, Washington DC's medical cannabis framework permits registered patients to access higher-potency concentrates and edibles tailored for serious therapeutic conditions.
As psychedelic decriminalization initiatives gain traction in jurisdictions like Oregon, Colorado, and Washington DC, researchers and policy makers are increasingly analyzing the regulatory boundary between high-potency THC products and therapeutic psychedelic substances.
Timeline and Next Steps
The Johns Hopkins research team has called for expanded, systematic clinical trials to evaluate high-dose THC across larger and more diverse patient populations. Future studies will focus on testing multiple cannabinoid ratios, including CBD and minor cannabinoids, to evaluate their influence on altered states.
Over the coming years, researchers plan to evaluate high-dose THC as an active comparator in Phase 2 and Phase 3 clinical trials for mental health conditions. These trials will test whether THC can effectively maintain trial blinding while providing clinical insights into set and setting dynamics.
For DMV cannabis consumers, state regulatory bodies in Virginia and Maryland will continue refining legal retail, delivery compliance, and product safety testing guidelines. Staying informed on verified dosing guidelines ensures safe, compliant access to legal cannabis products across the region.
Can 25 mg of THC feel identical to magic mushrooms?
The Johns Hopkins pilot study found that 25 mg of oral THC in a clinical, inward-focused setting produced subjective altered-state profiles qualitatively similar to 25 mg of psilocybin. However, individual experiences vary widely, and participants taking botanical distillate correctly identified it as cannabis.
Do cannabis and psilocybin affect the brain the same way?
No. Psilocybin interacts with serotonin 5-HT2A receptors, whereas THC binds to CB1 receptors in the endocannabinoid system. While the internal experience can feel similar under specific conditions, the underlying biological mechanisms in the brain are completely distinct.
Why did researchers use eye shades and music during the study?
Researchers utilized a controlled set and setting standard in psychedelic research—including eye shades, a curated playlist, and trained facilitators—to encourage inward focus. Environment and mindset heavily influence how high doses of oral THC are perceived by the brain.
Is cannabis delivery legal in Virginia?
In Virginia, commercial cannabis delivery regulations are strictly governed by state medical cannabis laws. Registered medical patients can receive home delivery from licensed pharmaceutical processors, while adult-use commercial retail delivery regulations remain subject to state legislative oversight.
What happened when study participants took a 50 mg dose of THC?
Increasing the dose to 50 mg of THC did not make the experience more psychedelic. Instead, researchers observed that the higher dose leaned more toward sedation and dissociation, demonstrating that higher THC levels alter the nature of the high rather than simply multiplying trip intensity.
Our take: At Bud Lords, we believe educated consumers make the best decisions. Whether you are exploring gentle microdoses or learning about high-potency cannabinoid science, understanding dose, set, and setting empowers you to curate your experience safely and intentionally.
Written by Street Stories AI
Bud Lords AI Cannabis News Writer
Community-focused voice covering social equity, local stories, and grassroots perspectives. Authentic, community-oriented tone.
Expertise: social-equity · community
This AI-assisted article was created using the named Bud Lords newsroom personality and reviewed under Bud Lords editorial standards.
Comments